about
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsA very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTAbsence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion.Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection.Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health ServiceThe genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.Calibrated real-time PCR assay for quantitation of human herpesvirus 8 DNA in biological fluids.High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy.Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infectionInfection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, CubaSex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects.Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupRecommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT).Impact of pre-therapy viral load on virological response to modern first-line HAART.A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area.Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production.Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV-infected over the period 2004-2012 in the Veneto Region, Italy.The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals.Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy.Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma.
P50
Q28481038-6F64E9D7-D363-462C-9FAD-F04E23FDD875Q28542548-3431839C-9356-4CA4-BE1C-32E01768A9B9Q30630850-36C68078-BAA1-43E4-8CFA-9961F99E4277Q30843946-4D370C7D-6094-4D8C-811C-DFB5D2C54822Q33645832-1AAF8983-275F-4E36-9971-C1A0AC338700Q33800146-65955076-DFAF-4FE6-8E0D-A2779D2BEE87Q33999316-6CF5F886-D860-42E9-871E-BCDD187E42AFQ34108775-4B6CF585-FB45-4539-9FBE-D88D1C9AB551Q34159738-FBFE0665-B7AC-4BD1-B88A-344919A70EFFQ34231589-A56E0FA5-1816-4E6A-A81B-E19446AE13B7Q34273315-E71E8D39-C5F4-42D9-929B-68013FB21C06Q34558508-FB564FF1-F4F8-4437-8342-12430A6FE505Q34846620-ED1D718D-C4DC-49BB-87A7-2FE6E0929CAEQ34973832-0099FE4E-84A1-480E-A853-4098C027DEB7Q34988603-96571938-7B6A-443E-90F3-54E0CFDEAD7AQ35156558-A0258712-EC89-419D-A822-359E3B86D250Q35689000-692A3132-4E8D-49D8-8D09-50B4C3C68313Q35913936-8A2DA298-C230-4EF0-A175-6D825AAC0E87Q35968753-A36FF60F-2143-427D-B296-900AF3D72BC8Q35991632-88E86C1C-8AE4-4927-AA79-CB1EE935828EQ36692454-9FC44557-E1BD-46FF-BA9B-245B843BF367Q36917426-143EE226-4B6A-4E7F-A040-7354E74A6034Q37042552-420321FB-F8F8-4643-B91D-7B1757CA6E32Q37500009-E07675A4-0E48-440A-9CEB-4A5DDEF2EA1EQ37530942-DB417CDC-8085-4ABF-A556-27FDC1735A0AQ38226627-1FA2752C-05F9-4DCD-977C-52AF25A9D5E6Q38427973-F1EA5F7E-7D3E-494A-A9AF-23A0BFC394A6Q38884285-B0C59B10-0FB4-481E-BF1B-9261F1967F00Q38959289-537BA013-41E2-43F9-81F1-C3C14A31BE29Q39135660-E8FA6D13-C987-4D0B-9610-B58ACAD4A1DBQ39165135-53304EB0-08D9-4738-BAAA-79A68ADA02F7Q39429683-47DC0FAD-6C15-4234-838B-5994392E6958Q39501136-CAFA270B-53FA-4EB7-9057-1358A9B66C41Q39746816-A7F3C527-CF22-4281-A040-14F8930A07ADQ40646752-8ECDA6FC-9D39-4E7B-9CDD-58CFE5C2FD77Q40720422-1FABF444-5260-41F5-BDDE-7C274AD75477Q41465991-8F4665BA-B092-4834-ABC3-B62FA4CEC57EQ41498436-110404A9-09BE-47BD-8D0D-D1342B97BA21Q41579095-51241BAF-F145-484B-9512-57E545798970Q41596424-48FFD64A-C94F-48A5-8065-5968E62F2A6E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Massimo Andreoni
@ast
Massimo Andreoni
@en
Massimo Andreoni
@es
Massimo Andreoni
@nl
Massimo Andreoni
@sl
type
label
Massimo Andreoni
@ast
Massimo Andreoni
@en
Massimo Andreoni
@es
Massimo Andreoni
@nl
Massimo Andreoni
@sl
prefLabel
Massimo Andreoni
@ast
Massimo Andreoni
@en
Massimo Andreoni
@es
Massimo Andreoni
@nl
Massimo Andreoni
@sl
P106
P1153
36841400900
P21
P31
P496
0000-0002-3205-9758